EGFR and neoplasm: By contrast, patients with tumours that are wild-type for EGFR have better outcomes with conventional platinum-based chemotherapy than EGFR TKIs and lack of an activating EGFR mutation could be considered a contraindication to EGFR TKI therapy [23].